CLLS - Cellectis S.A.
| Previous close | 1.9700 |
| Open | 1.9900 |
| Bid | 1.9100 x 1100 |
| Ask | 1.9900 x 800 |
| Day's range | 1.9400 - 2.0000 |
| 52-week range | 1.6800 - 4.1000 |
| Volume | |
| Avg. volume | 68,674 |
| Market cap | 111.456M |
| Beta (5Y monthly) | 2.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.80 |
- Reuters
French biotech Cellectis takes stake in Mayflower-backed startup Primera
Cellectis, which gets a seat on Primera's board, will collaborate with Primera on the development of therapies for mitochondrial diseases, a group of genetic disorders. Under terms of the deal, if Primera chooses to exclusively license up to five co-developed therapies from Cellectis, it will be eligible to get up to $750 million in milestone payments.
ZacksIovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
- Zacks
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
- Zacks
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
ZacksStrength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ZacksSeer, Inc. (SEER) Stock Jumps 12.9%: Will It Continue to Soar?
Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.